Triggering receptor expressed on myeloid cells 1 (TREM1) (TREM1)

Triggering receptor expressed on myeloid cells 1 (TREM1) is a cell surface receptor belonging to the immunoglobulin superfamily, primarily expressed on neutrophils and monocytes. It acts as a potent amplifier of the innate immune response by stimulating the production of pro-inflammatory cytokines and chemokines upon activation through its association with the adaptor protein DAP12 [15, 26]. TREM1 plays a critical role in the pathogenesis of acute and chronic inflammatory conditions, including sepsis, where its soluble form (sTREM1) serves as a diagnostic and prognostic biomarker [24, 26]. In oncology, TREM1 is involved in the modulation of the tumor microenvironment and is considered a potential target for immunotherapy [5, 16]. Therapeutic strategies targeting TREM1, such as the peptide inhibitor nangibotide, aim to dampen excessive inflammatory responses without completely compromising host defense [26]. Note that the term "Myeloid receptor" is broad and can also refer to other proteins such as TREM2 or CD33 depending on the clinical context [36, 40].

Other names

TREM-1CD354Triggering receptor expressed on myeloid cellsMyeloid receptor

TREM1 inhibition (antagonism) or blocking of TREM1-ligand interaction to dampen inflammatory amplification.